Pfizer triumphs at environmental awards

Pfizer has been recognised as a leader in environmental excellence at the recent Business Commitment to the Environment (BCE) awards. Twelve companies received recognition...

CORRECTION: MabThera recommended in Scotland

Scottish physicians are now able to prescribe MabThera (rituximab) on the NHS, following a positive recommendation by the Scottish Medicines Consortium (SMC). MabThera was...

GPs need swine flu guidance

A poll of GPs by has revealed that, so far, only 9% of GPs in the UK have been given regular, clear and concise...

Tamiflu discount for poorer countries

Roche is to provide its antiviral Tamiflu at a lower price to developing countries as part of a new initiative. Under the Tamiflu Reserves...

Viruses resistant to Tamiflu identified

Several cases of the H1N1 ‘swine flu’ virus have emerged that are resistant to antiviral drug Tamiflu (oseltaminvir). WHO has been informed by...

Novo Nordisk launches Victoza in UK

Novo Nordisk’s Victoza is now available for type 2 diabetes patients in the UK, following EU approval. Victoza is the first once-daily human Glucagon-like...

Novartis joins fight against malaria

Novartis has become the first healthcare company to join United Against Malaria (UAM), a pan-Africa campaign to end malaria-related deaths and suffering by 2015....

Best-selling drugs cheaper in Europe

European prices of 170 best-selling drugs averaged 40% less than US prices in 2008, recent research has revealed. Within Europe, it was found,...

Study confirms Cervarix efficacy

The largest efficacy trial of a cervical cancer vaccine has shown that Cervarix protects against the five most common cancer-causing virus types. The...

Positive CHMP opinion for Javlor

The CHMP has issued a positive opinion recommending EU marketing authorisation for Javlor from Laboratoires Pierre Fabre. The drug has been recommended for...

Latest articles

focus on science and not geography

Greater global collaboration: Time to focus on science and not geography

The Pistoia Alliance is urging industry stakeholders worldwide to focus on science and not geography, in a call for greater global collaboration. More than 250...
Accelerating the MedTech landscape

Accelerating the MedTech landscape

The Academic Health Science Networks (AHSN) in partnership with the Association of British HealthTech Industries (ABHI) has launched a report on accelerating the MedTech...
Tescaro present data from the GARNET study on dostarlimab in endometrial cancer. 

Tescaro present data on dostarlimab in endometrial cancer

Tescaro release positive results from the GARNET study on dostarlimab in endometrial cancer.  TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, presents data from the...

Popular articles

Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Smart phone image: Digital partnerships in pharma

Digital partnerships in pharma and the NHS

Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
Trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial

Analysis of trial results of Brilinta for heart attack patients following thrombolysis

Analysis of trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial. The secondary...
The future of genomics

The future of genomics and precision medicine

How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Lixiana for Atrial Fibrillation

Daiichi Sanko announce results of two studies in the Edoxaban Clinical Research Programme

Daiichi Sankyo Company, Limited announces results from ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study assessing the safety and efficacy...